ndr takeaway strategi align
turnaround execut
earlier week host investor meet manag
resound feedback need execut clearli
challeng year given salesforc turnov cynosur rev drive share
sinc end vs said reason
optimist around busi fundament manag incent
well align sharehold drive turnaround believ guidanc
reset level leverag organ growth drive faster earn
growth beyond reiter overweight rate would like thank
cfo bob mcmahon ir mike watt host meet us
observ overal continu believ carri number
advantag market leader across healthi market segment medic
aesthet manag gave addit color help affirm view
better salesforc product drive segment growth manag recogn
ultim need deliv actual result expect return growth
cynosur region result highlight magnitud
salesforc disrupt took place unit state product
major opportun diagnost think opportun take share
mdx amidst period industri consolid panther one
broadest menu industri recent addit viral load fusion
last quarter breast health continu believ busi
grow low-singl digit increas level profit driven servic
growth new product intern opportun expect intern
continu growth engin number year capit
deploy remain major opportun advoc addit
share repurchas given current trade multipl manag incent
well align sharehold tie expans total sharehold return
return equiti ttm
link barclay live interact chart
dear client appreci consider institut investor all-america
equiti research survey view year roster pleas click
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product launch
add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
earlier week host investor meet manag resound
feedback need execut clearli challeng year
given salesforc turnov cynosur rev drive share sinc
end vs said reason optimist around
busi fundament manag incent well align sharehold
drive turnaround believ guidanc reset level
leverag organ growth drive faster earn growth beyond reiter
overweight rate would like thank cfo bob mcmahon ir mike watt
host meet us
overal continu believ carri number advantag market
leader across healthi market segment product offer across holog four
busi segment clearli differ also see number similar us
domin market leader market compet breast
mammographi gyn surgic molecular dx sexual health medic
aesthet broadli intern signific opportun improv market
penetr continu focu across portfolio new product momentum appear
acceler drive increment contribut organ growth
next sever year describ detail think breadth new product across
segment under-appreci continu innov engin
consist growth time collect busi gener signific free cash flow
re-deploy augment growth time variou busi may
ebb flow dont believ reason short-term disrupt one
busi creat enough nois impact entir enterpris
segment growth overal organ revenu growth
pleas see report
need execut
medic aesthet manag gave addit color help affirm
view better salesforc product drive growth segment manag
recogn ultim need deliv actual result expect
return growth interact physician
recent survey work clear us medic aesthet market healthi
cynosur good product cfo bob mcmahon note believ medic
aesthet market continu robust industri expect grow
hsd-ldd forese futur driven awar improv technolog
manag highlight competitor continu post solid growth sign
health market region cynosur perform afflict area
lack salesperson growth cynosur healthi
compani larg reli distribut domest manag run
analys go territori territori salesperson salesperson product product
note obviou gap salesforc impact growth
manag seen sign improv ramp take longer initi
expect led reset guidanc new segment leadership kevin
thornal implement august feel good salesforc hire
train almost posit fill new salesforc alreadi contribut
win manag highlight announc lightrx adopt
sculpsur comprehens head head analysi nifr devic compani
began roll direct-to-consum market target market
similar techniqu use geniu mammographi campaign manag
note seen nice uptak term web hit convers offic
visit sculpsur good news organ product
compani aim normal cadenc new product launch drive
growth sinc acquisit close expand indic use
sculpsur nifr also launch new rf platform tempsur
miss link execut understand difficult
compet cynosur salesforc turned-ov past year
manag note believ pay structur align industri peer
attract retain top talent realiz medic aesthet differ market
tradit busi salesforc compens align drive
success align sale compens focu capit sale
trail revenu pac-key consum previous cynosur salesforc
compens consum piec revenu simpli laser sale
salesforc would commun custom ever believ
salesforc fulli product enter cynosur salesforc
attrit took place wave first took place transact close
second took place shortli thereaft third wave consciou
cull compani upgrad talent cfo mcmahon note collect
salesforc turn past year half split first
two wave final wave doesnt anticip chang
salesforc improv product month certainli put
cynosur good foot head continu pleas
talent hire train place make growth driver
compani cynosur previou salesforc mental man
formal train program place cfo mcmahon note one top cynosur
sale leader stay run train program entiti
place last quarter
cynosur region result highlight magnitud salesforc disrupt took
place unit state disclos unit state repres
cynosur revenu drop
impli us cynosur sale declin sale increas
believ salesforc product key swing factor could drive
upsid given manag new guidanc assum modest ramp
prior acquisit cynosur estim cynosur roughli us sale
repres gener around million annual sale note
approxim hire complet point believ guidanc
assum much lower level initi product around million per quarter
end look forecast overal cynosur growth
impli product improv around per rep addit
gener per salesperson equat million annual cynosur
revenu around segment growth year signific disrupt
case made result acceler continu monitor
salesforc product close
cynosur region result show conservat manag guidanc around product fy end sept mm
note red dash line denot last full quarter cynosur prior acquisit
diagnost think opportun take share mdx amidst
period industri consolid panther one broadest menu
industri recent addit viral load fusion last
quarter market leader play diagnost includ mdx
sexual health panther workflow well cervic cancer screen
thinprep continu believ consolid test one key theme
coverag panther system optim posit aggreg share
time compani aggreg share lab
consolid also lab look consolid number instrument util
within lab panther workflow offer advantag custom given low cost
assay autom random-access capabl low hands-on time high-throughput
think risk opportun reimburs balanc
recur question meet given jan implement
protect access medicar act pama directli impact
reimburs cut though pressur compani lab custom turn could
pressur kit price said dx price headwind certainli new phenomenon
compani seen price headwind annual worth note
vast major std test cover privat payor medicar
impact pama view menu expans sustain growth driver
pleas see report
us sale per sale per rep us sale per sale per rep ttm barclay holog inc
sever year given custom renew
contract annual basi panther system place world-wide
consum pull-through per
util note disciplin effort underway drive cross-sel
menu custom account-by-account basi
molecular diagnost growth panther instal base
upcom renew nation lab increas focu
investor like lab look extract price concess upon
renew factor leverag off-set pressur menu
expans viral load ldt think unlik get displac
renew given manufactur full breadth sexual
health assay fda approv high-throughput platform roch seriou
diagnost contend contract said sexual health roch current
ct/ng fda approv highest-throughput coba platform hpv
trichomona mdx platform also offer non-monetari valu
lab given sizabl ob/gyn salesforc drive test adher guidelin
benefit nation lab increas test volum good exampl
trichomona essenti creat categori test final would
transit cost potenti disrupt oper one nation lab
switch vendor imposs major headach
molecular diagnost landscap menu breadth
breast health continu believ busi grow low-singl
digit increas level profit driven servic growth new product
intern opportun start mammographi us system placement
segment revenu rel stabl placement
quarter tout tier approach taken mammographi platform
new high end system custom want bell
whistl new low end system perform commun hospit want
latest technolog price within tier stabl gross margin par
across platform new product backward compat note
competit dynam us stabl estim place
new system versu aggreg instal base market share
ge siemen second gener devic within
market share data suggest made substanti inroad price
stabl around around addit note
opportun new softwar drive revenu profit growth
amongst current instal base instrument unlik prior product launch new
softwar upgrad design compat compani current instal
base abil go back drive increment add-on
custom drop earn
highlight traction new product includ
affirm brevera affirm compani new biopsi tabl compat
mammographi system affirm sale contribut revenu
believ continu step next sever year brevera compani
new intervent tool biopsi expect contribut around segment
growth year brevera integr affirm biopsi tabl mammographi
instrument capit compon sale lower steadi trail
consum revenu needl sale allow continu drive
durabl revenu growth segment
sexual healthvir loadrespiratorytransplantationhaicompanion dxcompanyinstrumentlaunchs placedsampl per shiftct/nghpvhsv a/b/rsvadv/hmpv/rvparaflucmvebvhsvvzvbkvc cyclerallallallallamplicor ampliprepallallallallcoba indic fda pma approvaleu indic ce-ivd approvalal indic us euro approv barclay holog inc
holog placement penetr instal base
expect intern continu growth engin number
year overal intern repres around revenu
reflect histor under-focu market rather lack product market
develop holog competitor balanc
term
domestic/intern revenu split leadership structur evolv time
region leader europ asia latin america manag underneath
franchis countri focu leader expect
manag compet exact competitor across
geographi increas focu build relationship dealer
improv go-to-market strategi last year complet tuck-in
 distributor germani spain improv direct exposur region
improv margin captur manag note increas
win rate custom region breast health develop
partnership agreement phillip earli better compet tender
opportun intern market histor variou countri
tender carv countri would run tender
entir radiolog suit holog expertis mammographi phillip strength
imag technolog combin effort better compet ge
siemen front
capit deploy remain major opportun advoc
addit share repurchas given current trade multipl stock
price-to-earnings current forecast revenu billion free
cash flow million leverag net debt ebitda squar within
manag target rang impli futur free cash flow re-
deploy augment growth bolt-on manag prefer use cash
follow share repurchas manag ad look
transform acquisit bolt-on deal would cover year cash flow
compani look near-term accret runway take place
quickli develop deal time aesthet market ripe
consolid numer small under-capit busi said clearli
manag need demonstr turnaround cynosur first prove
establish channel place leverag acquisit manag incent well
align sharehold tie expans total sharehold return
opportunist repurchas million share believ
unit placement unit barclay holog inc
buy-back would send bullish signal market readi turn
share repurchas ep accret stock price
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
